Publications (51) Publications auxquelles un chercheur a participé

2024

  1. Erythematous papule after patch testing. Is all that glitters really gold?

    Annales de Dermatologie et de Venereologie

  2. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  3. Multidisciplinary boards: Survey on the current situation and needs of Spanish radiologists

    Radiologia, Vol. 66, Núm. 6, pp. 526-541

  4. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  5. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

2023

  1. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

    Hematology (United Kingdom), Vol. 28, Núm. 1

  2. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

  3. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 10, pp. e341-e347

2022

  1. Diffuse bone marrow metastases of small cell carcinoma with associated erythrophagocytosis mimicking acute leukaemia

    Hematology, Transfusion and Cell Therapy, Vol. 44, Núm. 3, pp. 459-461

  2. Treatment burden in multiple myeloma according to comorbidity in real life

    Annals of Hematology

  3. Urgent and unexpected findings in oncology and hematology patients: a practical approach to imaging

    Radiologia, Vol. 64, Núm. 5, pp. 464-472

  4. Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma

    European Journal of Haematology

2021

  1. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

  2. Faggot cells in therapy-related acute myeloid leukemia with inv(16)

    Clinical Case Reports, Vol. 9, Núm. 1, pp. 572-573

  3. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  4. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  5. Learning How to Order Imaging Tests and Make Subsequent Clinical Decisions: a Randomized Study of the Effectiveness of a Virtual Learning Environment for Medical Students

    Medical Science Educator, Vol. 31, Núm. 2, pp. 469-477

  6. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  7. MPL S505C enhances driver mutations at W515 in essential thrombocythemia

    Blood Cancer Journal

  8. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420